Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methyldopa

FDA-approved product (tablet, oral), marketed as Aldomet, Methyldopa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Methyldopa
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Methyldopa
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methyldopa in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methyldopa with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

    NCT01470859 · start 2011-12

    Registered record
    Registry ID
    NCT01470859
    Conditions
    Idiopathic Parkinson's Disease
    Interventions
    pramipexole; Sinemet CR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinson's Disease
    Interventionpramipexole; Sinemet CR
    PhaseNot applicable
    Registry statusCompleted

  • Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

    NCT01479127 · start 2011-10

    Registered record
    Registry ID
    NCT01479127
    Conditions
    Advanced Parkinson's Disease
    Interventions
    ABT-SLV187; Oral Levodopa/Carbidopa; Infusion Pump: CADD-Legacy® 1400 Pump; NJ-Tube: Silicon ED Tube; Adaptor: Hakko Adaptor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Parkinson's Disease
    InterventionABT-SLV187; Oral Levodopa/Carbidopa; Infusion Pump: CADD-Legacy® 1400 Pump; NJ-Tube: Silicon ED Tube +1 more
    PhasePhase 2
    Registry statusCompleted

  • Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

    NCT01674127 · start 2011-08

    Registered record
    Registry ID
    NCT01674127
    Conditions
    Pregnant Women With Mild Preeclampsia
    Interventions
    Methyldopa; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women With Mild Preeclampsia
    InterventionMethyldopa; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)

    NCT01361425 · start 2011-05

    Registered record
    Registry ID
    NCT01361425
    Conditions
    Preeclampsia
    Interventions
    methildopa; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia
    Interventionmethildopa; placebo
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

    NCT01766258 · start 2011-05

    Registered record
    Registry ID
    NCT01766258
    Conditions
    Parkinson's Disease
    Interventions
    ODM-101 65mg Carbidopa; ODM-101 105mg Carbidopa; Stalevo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-09
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionODM-101 65mg Carbidopa; ODM-101 105mg Carbidopa; Stalevo
    PhasePhase 2
    Registry statusCompleted

  • Levodopa Concentration Profile With Stalevo 75/125 mg

    NCT01070628 · start 2009-12

    Registered record
    Registry ID
    NCT01070628
    Conditions
    Parkinson's Disease
    Interventions
    Stalevo (levodopa/ carbidopa/ entacapone); Sinemet (levodopa/carbidopa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-12
    Completion
    2010-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionStalevo (levodopa/ carbidopa/ entacapone); Sinemet (levodopa/carbidopa)
    PhasePhase 1
    Registry statusCompleted

  • Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia

    NCT01212484 · start 2009-12

    Registered record
    Registry ID
    NCT01212484
    Conditions
    Familial Dysautonomia
    Interventions
    Carbidopa; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12
    Completion
    2012-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Dysautonomia
    InterventionCarbidopa; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects

    NCT00914602 · start 2009-05

    Registered record
    Registry ID
    NCT00914602
    Conditions
    Parkinson's Disease
    Interventions
    Sinemet 25-100 Oral Tablet; XP21279; Carbidopa Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionSinemet 25-100 Oral Tablet; XP21279; Carbidopa Pill
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

    NCT00845000 · start 2009-04-21

    Registered record
    Registry ID
    NCT00845000
    Conditions
    Parkinson Disease
    Interventions
    SCH 420814 10 mg; SCH 420814 100 mg; Placebo; Levodopa; Carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04-21
    Completion
    2010-05-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionSCH 420814 10 mg; SCH 420814 100 mg; Placebo; Levodopa +1 more
    PhasePhase 1
    Registry statusCompleted

  • High and Low Dose Carbidopa Treatment of Parkinson's Disease

    NCT01399905 · start 2009-03

    Registered record
    Registry ID
    NCT01399905
    Conditions
    Parkinson's Disease
    Interventions
    carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Interventioncarbidopa
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

    NCT01533077 · start 2009-03

    Registered record
    Registry ID
    NCT01533077
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Sinemet® 100/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Sinemet® 100/25 mg
    PhasePhase 1
    Registry statusCompleted

  • PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

    NCT00562198 · start 2008-01

    Registered record
    Registry ID
    NCT00562198
    Conditions
    Parkinson´s Disease
    Interventions
    entacapone and carbidopa; Sinemet 200mg/50mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2008-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson´s Disease
    Interventionentacapone and carbidopa; Sinemet 200mg/50mg
    PhasePhase 2
    Registry statusTerminated

  • A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects

    NCT00460954 · start 2007-06

    Registered record
    Registry ID
    NCT00460954
    Conditions
    Parkinson's Disease
    Interventions
    Sinemet® controlled release (Carbidopa/levodopa)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionSinemet® controlled release (Carbidopa/levodopa)
    PhaseNot recorded
    Registry statusCompleted

  • Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

    NCT00141518 · start 2006-03

    Registered record
    Registry ID
    NCT00141518
    Conditions
    Advanced Idiopathic Parkinson's Disease
    Interventions
    Levodopa-carbidopa intestinal gel (LCIG); CADD-Legacy® 1400 ambulatory infusion pump; percutaneous endoscopic gastrostomy tube (PEG tube); jejunal extension tube (J-tube)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2011-04
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Idiopathic Parkinson's Disease
    InterventionLevodopa-carbidopa intestinal gel (LCIG); CADD-Legacy® 1400 ambulatory infusion pump; percutaneous endoscopic gastrostomy tube (PEG tube); jejunal extension tube (J-tube)
    PhasePhase 4
    Registry statusCompleted

  • Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia

    NCT00117546 · start 2005-09

    Registered record
    Registry ID
    NCT00117546
    Conditions
    Preeclampsia
    Interventions
    alpha methyldopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2005-09
    Completion
    2008-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia
    Interventionalpha methyldopa
    PhasePhase 4
    Registry statusUnknown